216 related articles for article (PubMed ID: 37175629)
21. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
23. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
24. A Novel and Robust Long Noncoding RNA Panel to Predict the Prognosis of Pancreatic Cancer.
Li M; Li H; Chen Q; Wu W; Chen X; Ran L; Si G; Tan X
DNA Cell Biol; 2020 Jul; 39(7):1282-1289. PubMed ID: 32522048
[TBL] [Abstract][Full Text] [Related]
25. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
Zhang X; Zhou Y; Hu J; Yu X; Xu H; Ba Z; Zhang H; Sun Y; Wang R; Du X; Mou R; Li X; Zhu J; Xie R
BMC Cancer; 2023 Jun; 23(1):560. PubMed ID: 37330494
[TBL] [Abstract][Full Text] [Related]
27. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.
Wang C; Wang Z; Zhao Y; Jia R
BMC Gastroenterol; 2022 Nov; 22(1):495. PubMed ID: 36451085
[TBL] [Abstract][Full Text] [Related]
28. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
29. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
30. Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma.
Li L; Xiao Z; He P; Zou W; Deng Z; Zhang G; Liu R
BMC Gastroenterol; 2022 Nov; 22(1):454. PubMed ID: 36371178
[TBL] [Abstract][Full Text] [Related]
31. System Analysis Based on Pancreatic Cancer Progression Identifies BRINP2 as a Novel Prognostic Biomarker.
Kang Y; Xu X; Liu J
Crit Rev Eukaryot Gene Expr; 2023; 33(7):1-16. PubMed ID: 37602449
[TBL] [Abstract][Full Text] [Related]
32. LINC00941 promotes proliferation and metastasis of pancreatic adenocarcinoma by competitively binding miR-873-3p and thus upregulates ATXN2.
Fang L; Wang SH; Cui YG; Huang L
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1861-1868. PubMed ID: 33660796
[TBL] [Abstract][Full Text] [Related]
33. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients.
Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M
Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis-Related Gene
Fang Z; Wang W; Liu Y; Hua J; Liang C; Liu J; Zhang B; Shi S; Yu X; Meng Q; Xu J
Curr Oncol; 2023 Mar; 30(3):2997-3019. PubMed ID: 36975441
[TBL] [Abstract][Full Text] [Related]
35. Prognostic prediction of head and neck squamous cell carcinoma: Construction of cuproptosis-related long non-coding RNA signature.
Huang Q; You Q; Zhu N; Wu Z; Xiang Z; Wu K; Ren J; Gui Y
J Clin Lab Anal; 2022 Nov; 36(11):e24723. PubMed ID: 36189780
[TBL] [Abstract][Full Text] [Related]
36. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo.
Wang Z; Yuan Q; Chen X; Luo F; Shi X; Guo F; Ren J; Li S; Shang D
Funct Integr Genomics; 2023 Aug; 23(3):263. PubMed ID: 37540295
[TBL] [Abstract][Full Text] [Related]
37. A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma.
Zhang G; Sun J; Zhang X
Sci Rep; 2022 Jul; 12(1):11325. PubMed ID: 35790864
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
39. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]